Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments (2016 - 2026)

Spyre Therapeutics has reported Change in Acquisitions & Divestments for 11 years, with the latest figure at $107.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 50.94% year-over-year to $107.7 million; the trailing twelve-month figure through Mar 2026 stood at $408.1 million (up 51.37% YoY), and the FY2025 full-year result was $371.7 million, up 51.13% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $107.7 million, up from $94.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $107.7 million in Q1 2026, with the low at $3.2 million in Q2 2023.
• Historically, Change in Acquisitions & Divestments has averaged $53.9 million across 5 years, with a median of $52.8 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 87.0% — and 2024, when it soared 1680.8%.
• Spyre Therapeutics' Change in Acquisitions & Divestments stood at $18.5 million in 2022, then climbed by 2.16% to $18.9 million in 2023, then jumped by 230.94% to $62.5 million in 2024, then jumped by 50.76% to $94.3 million in 2025, then gained by 14.26% to $107.7 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $107.7 million (Q1 2026), $94.3 million (Q4 2025), and $99.2 million (Q3 2025), per Business Quant data.